Kazakhstan has entered a brand new part of cooperation with British-Swedish pharmaceutical big AstraZeneca, increasing the partnership past healthcare into science, schooling, and innovation.
On January 26, Minister of Science and Higher Education Sayasat Nurbek visited AstraZeneca’s Discovery Centre in Cambridge, the corporate’s largest international analysis and innovation hub, the place a memorandum of understanding was signed with AstraZeneca Kazakhstan.
According to the ministry, the settlement paves the way in which for brand spanking new areas of collaboration geared toward strengthening nationwide scientific capability, introducing superior medical applied sciences, and enhancing the long-term sustainability of Kazakhstan’s healthcare system.
The partnership will concentrate on a number of strategic areas:
- Real-World Data (RWD) and Real-World Evidence (RWE): Development of superior information analytics instruments to assist scientific analysis, scientific decision-making, and evidence-based healthcare coverage.
- Expansion of the Young Health Program: Prevention of non-communicable illnesses amongst youth and the promotion of accountable well being behaviors.
- Sustainable Development and Economic Diversification: Joint initiatives in environmental safety, inexperienced applied sciences, and sustainable enterprise practices.
- Early Diagnosis and Healthcare Resilience: Implementation of contemporary screening strategies, specialist coaching, and improvement of diagnostic infrastructure.
Nurbek highlighted that the memorandum creates new alternatives to combine analysis, schooling, and real-world scientific follow.
“It is important not only to develop fundamental science, but also to ensure the transfer of advanced technologies and data into everyday medical practice. This partnership strengthens Kazakhstan’s scientific and biomedical potential,” he stated.
AstraZeneca has steadily expanded its operations in Kazakhstan in recent times.
In April 2024, the Ministry of Healthcare, the Almaty metropolis administration, nationwide funding company Kazakh Invest, and AstraZeneca signed an settlement on the contract manufacturing of biotechnological merchandise. The initiative helps Kazakhstan’s strategic objective of accelerating the share of domestically produced medicines to 50%.
In July 2024, AstraZeneca and the state pharmaceutical distributor SK-Pharmacy signed a long-term settlement on native manufacturing and expertise switch.
According to Maria Shipuleva, CEO of AstraZeneca Kazakhstan, the corporate’s progressive medicines might be produced on the Nobel Almaty Pharmaceutical Factory. The manufacturing portfolio consists of remedies for diabetes, power coronary heart failure, power kidney illness, a number of types of leukemia, and most cancers therapies for breast, ovarian, prostate, and pancreatic cancers.